| 511 |
Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors |
Department of Pharmaceutical Organic Chemistry |
2020 |
| 512 |
Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors |
Department of Pharmaceutical Organic Chemistry |
2020 |
| 513 |
Design and Synthesis of Novel Isatin-Based derivatives Targeting Cell Cycle Checkpoint Pathways as Potential Anticancer Agents |
Department of Medicinal Chemistry |
2020 |
| 514 |
Design and Synthesis of Novel Isatin-Based derivatives Targeting Cell Cycle Checkpoint Pathways as Potential Anticancer Agents |
Department of Medicinal Chemistry |
2020 |
| 515 |
Design and Synthesis of Novel Isatin-Based derivatives Targeting Cell Cycle Checkpoint Pathways as Potential Anticancer Agents |
Department of Medicinal Chemistry |
2020 |
| 516 |
Design and Synthesis of Novel Isatin-Based derivatives Targeting Cell Cycle Checkpoint Pathways as Potential Anticancer Agents |
Department of Medicinal Chemistry |
2020 |
| 517 |
Design and Synthesis of Novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases |
Department of Pharmaceutical Organic Chemistry |
2020 |
| 518 |
Design and synthesis of some 1,3,5-tri-substituted oxindole derivatives as potential CDK inhibitors |
Department of Medicinal Chemistry |
2020 |
| 519 |
Design and synthesis of some 1,3,5-tri-substituted oxindole derivatives as potential CDK inhibitors |
Department of Medicinal Chemistry |
2020 |
| 520 |
Design and synthesis of some 1,3,5-tri-substituted oxindole derivatives as potential CDK inhibitors |
Department of Medicinal Chemistry |
2020 |